WallStSmart

Fresenius Medical Care Corporation (FMS)vsGuardian Pharmacy Services, Inc. (GRDN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 1255% more annual revenue ($19.63B vs $1.45B). FMS leads profitability with a 5.0% profit margin vs 3.4%. FMS trades at a lower P/E of 11.2x. FMS earns a higher WallStSmart Score of 62/100 (C+).

FMS

Buy

62

out of 100

Grade: C+

Growth: 5.3Profit: 5.0Value: 10.0Quality: 7.0
Piotroski: 6/9Altman Z: 1.82

GRDN

Hold

46

out of 100

Grade: D+

Growth: 6.7Profit: 7.0Value: 5.7Quality: 5.8
Piotroski: 3/9Altman Z: 6.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+73.4%)

Margin of Safety

+73.4%

Fair Value

$90.32

Current Price

$22.26

$68.06 discount

UndervaluedFair: $90.32Overvalued
GRDNSignificantly Overvalued (-552.6%)

Margin of Safety

-552.6%

Fair Value

$5.30

Current Price

$37.57

$32.27 premium

UndervaluedFair: $5.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

PEG RatioValuation
0.738/10

Growing faster than its price suggests

GRDN3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
6.0610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
26.6%9/10

Every $100 of equity generates 27 in profit

Revenue GrowthGrowth
17.4%8/10

17.4% revenue growth

Areas to Watch

FMS4 concerns · Avg: 3.5/10
EPS GrowthGrowth
4.2%4/10

4.2% earnings growth

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
7.9%3/10

ROE of 7.9% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
3.4%3/10

3.4% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.

Bear Case : FMS

The primary concerns for FMS are EPS Growth, Altman Z-Score, Return on Equity. Thin 5.0% margins leave little buffer for downturns.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, EPS Growth, Profit Margin. A P/E of 48.2x leaves little room for execution misses. Thin 3.4% margins leave little buffer for downturns.

Key Dynamics to Monitor

FMS profiles as a value stock while GRDN is a growth play — different risk/reward profiles.

GRDN is growing revenue faster at 17.4% — sustainability is the question.

FMS generates stronger free cash flow (564M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FMS scores higher overall (62/100 vs 46/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions for the long-term care sector, which includes assisted living and skilled nursing facilities. The company is distinguished by its commitment to personalized medication management, ensuring high standards of quality and compliance while delivering exceptional customer service. Leveraging advanced technology and deep pharmaceutical expertise, Guardian aims to enhance patient outcomes and streamline workflows for its healthcare partners. With a strong operational presence across multiple states, the company is well-positioned to address the growing needs for tailored pharmacy services amidst an evolving healthcare landscape.

Want to dig deeper into these stocks?